ResearcherNantong UniversityActive in the last 2 years

Meng Zhang

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 8 November 2026

Known by name at one institution; no external author ID yet. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2024: 1 paper

Papers 1

KLK10/LIPH/PARD6B/SLC52A3 are promising molecular biomarkers for the prognosis of pancreatic cancer through a ceRNA network. Co-author DOI 10.1016/j.heliyon.2024.e24287 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xiaomei Tang · 1 shared paper, 2024 · strength 0.18
- Paper KLK10/LIPH/PARD6B/SLC52A3 are promising molecular biomarkers for the prognosis of pancreatic cancer through a ceRNA net… DOI 10.1016/j.heliyon.2024.e24287 ↗
Da Fu · 1 shared paper, 2024 · strength 0.18
- Paper KLK10/LIPH/PARD6B/SLC52A3 are promising molecular biomarkers for the prognosis of pancreatic cancer through a ceRNA net… DOI 10.1016/j.heliyon.2024.e24287 ↗
Hong Yu · 1 shared paper, 2024 · strength 0.18
- Paper KLK10/LIPH/PARD6B/SLC52A3 are promising molecular biomarkers for the prognosis of pancreatic cancer through a ceRNA net… DOI 10.1016/j.heliyon.2024.e24287 ↗
Yu‐Shui Ma · 1 shared paper, 2024 · strength 0.18
- Paper KLK10/LIPH/PARD6B/SLC52A3 are promising molecular biomarkers for the prognosis of pancreatic cancer through a ceRNA net… DOI 10.1016/j.heliyon.2024.e24287 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.